Market Overview

Bluebird Bio: Here's Why Wedbush Is Bullish

Share:

In a report published Thursday, Wedbush Morgan analyst David Nierengarten maintained an Outperform rating on bluebird bio, Inc (NASDAQ: BLUE), with a price target of $146.

In the report, Wedbush Morgan noted, "BLUE reported a 4Q net loss of $19.5M ($0.67), below our estimate and consensus ($0.58). The company is well financed, with $492M in cash on hand at YE14, sufficient in management's view to fund operations through 2017."

"Based on positive preliminary data presented at ASH, we expect the first SCD patient from the French HGB-205 study of LentiGlobin to achieve transfusion-independence in H1:15…Positive results would provide the first example of SCD being successfully treated with gene therapy. Given the greater prevalence (especially in the US) and awareness of SCD over beta-thal, the data should drive even greater lebvels of invester interest in BLUE," Nierengarten wrote.

"We expect the LentiGlobin Ph 1/2 studies Northstar in beta-thal (n=15) and HGB-205 in beta-thal and SCD (n=7) to complete enrollment this year, along with the Ph 2/3 Starbeam study of Lenti-D in CCALD (n=15). We expect enrollment in Starbeam, which has thus far been conducted in the US, to be expanded into Europe this year," the analyst added.

Latest Ratings for BLUE

DateFirmActionFromTo
Nov 2019UpgradesNeutralOutperform
Nov 2019MaintainsNeutral
Nov 2019MaintainsEqual-Weight

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Wedbush MorganAnalyst Color Analyst Ratings

 

Related Articles (BLUE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
WBCLSADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Social Media Analytics: 3 ETFs Recently Blowing Up On Twitter

IBM CEO Explains Confidence In Reaching $40B Revenue From 'Strategic Imperatives' By 2018